YX-2-107

Overview

YX-2-107 is a PROTAC ( IC 50 = 4.4 nM) that selectively degrades CDK6 . YX-2-107 effectively inhibits RB phosphorylation and FOXM1 expression in vitro and inhibits the development of Ph + ALL in rats. YX-2-107 can be used in the study of Ph chromosome-positive (Ph + ) acute lymphoblastic leukemia (ALL).

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Acute Lymphoblastic Leukemia | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > CDK | Products > Signaling Pathways > FOXM1

Product Information

• Catalog No.: HY-148530
• CAS No.: 2417408-46-7
• Molecular Formula: C45H51N11O9
• Molecular Weight: 889.95
• Purity: 98.60%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (2.81 mM); Clear solution
• Availability: In-stock

Source

Original product source